Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|November 20, 2025

Using TDMs to Improve Care and Communication

Author(s)Jonathan M. Meyer, MD, DLFAPA

Reviewing TDM’s evidence-based rationale, its clinical utility, and connection to outcomes.

Episodes in this series

EP. 1 Why Therapeutic Drug Monitoring Is Important for Antipsychotics

EP. 1 Why Therapeutic Drug Monitoring Is Important for Antipsychotics

EP. 2 Using TDMs to Improve Care and Communication

EP. 2 Using TDMs to Improve Care and Communication

EP. 3 A New Option: Getting TDM Data Faster

EP. 3 A New Option: Getting TDM Data Faster

EP. 4 Concluding Thoughts: Practical Tips, Resources, and More

EP. 4 Concluding Thoughts: Practical Tips, Resources, and More

drug monitoring

EP. 5 Precision Psychiatry in Practice: 3 Therapeutic Drug Monitoring Pearls

This video covers the following questions:

Can you walk us through the typical therapeutic range—and what factors can influence individual variability?
How can TDM help clinicians differentiate between treatment resistance due to pharmacokinetic factors (like metabolism) versus true nonresponse? and What role does TDM play in preventing toxicity, including dose-related adverse effects such as seizures or sedation?
How might TDM support patient adherence and shared decision-making in clinical practice?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Screening for MDD: Distinguishing Depression From Grief and Medical Mimics

ByGus Alva, MD ,Anita H. Clayton, MD,Charles Debattista, MD,Lara Shirikjian, MD ,Hara Oyedeji, DNP, PMHNP-BC

July 28th 2026

Recognizing MDD in Practice: Presentation, Risk Factors, and Delayed Diagnosis

ByGus Alva, MD ,Anita H. Clayton, MD,Charles Debattista, MD,Lara Shirikjian, MD ,Hara Oyedeji, DNP, PMHNP-BC

July 28th 2026

Experts featured in this series.

Multidisciplinary Approaches to Long-Term Narcolepsy Care

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 22nd 2026

Experts featured in this series.

Optimizing Narcolepsy Treatment Through Polypharmacy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 15th 2026

Experts featured in this series.

Assessing DEA Scheduling and Emerging Therapies in Narcolepsy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 15th 2026

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

The 5 Faces of Bipolar Depression: A Case-Based Reflection

Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?

Changes in Self-Awareness Following Traumatic Brain Injury: Assessment and Practical Treatment Considerations

Perimenopausal Depression May Signal a Hormonal Component: When to Consider HRT

Biomarker Testing for Alzheimer Disease: Inside the Latest P-Tau217 Data